NanoViricides financials
$1.30−13.33%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '26 Jun 30 | Q3 '26 Mar 31 | Q2 '26 Dec 31 | Q1 '26 Sep 30 | Q4 '25 Jun 30 | Q3 '25 Mar 31 | Q2 '25 Dec 31 | Q1 '25 Sep 30 | Q4 '24 Jun 30 | Q3 '24 Mar 31 | Q2 '24 Dec 31 | Q1 '24 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$2.2M | -$2.0M | -$2.2M | -$1.8M | -$2.1M | -$2.2M | -$2.1M | -$3.2M | -$2.4M | -$1.9M | -$2.2M | -$2.0M |
| Net income | -$2.2M | -$2.0M | -$2.2M | -$1.8M | -$2.1M | -$2.2M | -$2.0M | -$3.1M | -$2.4M | -$1.9M | -$2.1M | -$2.0M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.10 | $-0.09 | $-0.11 | $-0.10 | $-0.13 | $-0.14 | $-0.14 | $-0.23 | $-0.19 | $-0.16 | $-0.18 | $-0.17 |
| EBITDA | -$2.1M | -$1.9M | -$2.1M | -$1.7M | -$2.0M | -$2.1M | -$1.9M | -$3.0M | -$2.2M | -$1.7M | -$2.0M | -$1.8M |
| Operating cash flow | -$2.1M | -$1.9M | -$2.0M | -$1.6M | -$1.7M | -$2.0M | -$2.2M | -$2.6M | -$1.5M | -$1.9M | -$1.7M | -$1.2M |
| Free cash flow | -$2.1M | -$1.9M | -$2.0M | -$1.7M | -$1.7M | -$2.0M | -$2.2M | -$2.6M | -$1.6M | -$2.0M | -$1.7M | -$1.2M |
| Diluted shares | 22.2M | 21.6M | 19.9M | 17.1M | 16.2M | 16.0M | 14.6M | 13.7M | 12.2M | 11.8M | 11.7M | 11.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.8M | $3.2M | $5.2M | $1.1M | $1.6M | $2.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $9.9M | $10.2M | $12.3M | $8.4M | $8.8M | $10.0M |
| Total liabilities | $1.2M | $1.1M | $1.2M | $1.2M | $1.3M | $1.2M |
| Shareholders' equity | $8.7M | $9.2M | $11.1M | $7.2M | $7.5M | $8.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology